Scientists have worked to create a safe, lethal but non-addictive environment to combat the current opioid crisis, where opioid dependence is heavily dependent on pain relief.
New Pain Home
With the support of the National Institute of Drug Abuse, scientists from the Wake Forest University School of Medicine work to find safe and non-invasive pain reliefs to help combat the current opioid crisis in the country. Although it has been done in an animal model, the new chemical compound known as AT-121 is known as the double action that suppresses the addictive effects of opioids and produces morphine-like analgesic effects in non-human primates. "In our study, we found that AT-121 was safe and non-addictive, as well as an effective medication for pain," Dr. Mei Xuan-ku, professor of physiology and pharmacology at the School of Medicine and a member of the Wake Forest Medical Baptist Center. This composition is also effective in preventing potential opioid abuse, such as buprenorphine, so we hope it will be used to treat pain and opioid use. "The results of this study were published in the 29th August issue of Scientific Translation Medicine.
A New Study on Non-Addictive Pain Relief
The main purpose of this study was to provide a chemical compound To design and test what works on both opioid receptors, the main component of prescription painkillers and nicotine receptors that prevent abuse or prevention of abuse. For the side effects of target opioids, current opioids, such as fentanyl and oxicodone, function only on the opium receptor, which also unwanted side effects – respiratory problems, abuse, increased sensitivity to pain and physical dependence. -121 b collecting An appropriate balance in two activities in a single molecule, and that is what we think is better as the use of two drugs can combine their pharmaceutical strategy. "
In the study, the researchers noted that AT-121 had the same level of pain relief as opio but at a dose less than 100 times that of morphine, and at that rate also the addictive effects of oxicodone, a commonly abused drug, the AT 121 pain relief technique was effective, with no Abuse, but also had other opioid side effects, such as itching, respiratory problems, deviation and physical dependence on medication.
"Our data show that the future of oxyptin afionceptide not only recorded the side effects of addiction and other side effects, but also effective pain relief. The fact that this data is in non-human primates wash, It was also important because it proved that compounds, such as AT-121, have the potential to be a substitute for the prescribed opioids. "The following steps include additional preclinical studies to collect more safety data , and if everything goes well, On the Food and Drug Administration For approval for clinical trials, start on people, according to Kuo.
AT-121 was developed by dr. Norulain T. Zaffery, a member of the Astraea Therapeutics research team. This work has been supported by grants from the National Institute of Health and the National Institute for Drug Abuse. R01DA032568, R01DA027811, R44DA042465, R21DA040104, and R21DA044775, and the US Department of Defense W81XWH-13-2-0045.